Robert W Ledeen Selected Research

G(M1) Ganglioside

1/2020	Mice deficient in GM1 manifest both motor and non-motor symptoms of Parkinson's disease; successful treatment with synthetic GM1 ganglioside.
1/2018	Gangliosides, α-Synuclein, and Parkinson's Disease.
2/2016	Functional interplay between ganglioside GM1 and cross-linking galectin-1 induces axon-like neuritogenesis via integrin-based signaling and TRPC5-dependent Ca²⁺ influx.
1/2015	GDNF signaling implemented by GM1 ganglioside; failure in Parkinson's disease and GM1-deficient murine model.
10/2012	Deficiency of ganglioside GM1 correlates with Parkinson's disease in mice and humans.
4/2012	Beyond glycoproteins as galectin counterreceptors: tumor-effector T cell growth control via ganglioside GM1 [corrected].
4/2009	Cross-linking of GM1 ganglioside by galectin-1 mediates regulatory T cell activity involving TRPC5 channel activation: possible role in suppressing experimental autoimmune encephalomyelitis.
9/2002	Characterization of cholera toxin B subunit-induced Ca(2+) influx in neuroblastoma cells: evidence for a voltage-independent GM1 ganglioside-associated Ca(2+) channel.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robert W Ledeen Research Topics

Disease

5	Parkinson Disease (Parkinson's Disease) 01/2020 - 10/2012
5	Neuroblastoma 01/2018 - 06/2002
3	Seizures (Absence Seizure) 04/2006 - 11/2005
2	Neoplasms (Cancer) 02/2017 - 04/2012
2	Neurodegenerative Diseases (Neurodegenerative Disease) 08/2015 - 07/2015
1	Brain Injuries (Brain Injury) 08/2015
1	Carcinoma (Carcinomatosis) 04/2012
1	Parkinsonian Disorders (Parkinsonism) 09/2011
1	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 04/2009
1	Tremor (Tremors) 01/2009
1	Canavan Disease (Leukodystrophy, Spongiform) 01/2009
1	Status Epilepticus (Complex Partial Status Epilepticus) 11/2005

Drug/Important Bio-Agent (IBA)

8	G(M1) GangliosideIBA 01/2020 - 09/2002
6	GangliosidesIBA 01/2018 - 11/2005
4	LIGA 20IBA 09/2011 - 11/2005
2	Polysaccharides (Glycans)IBA 01/2018 - 02/2017
2	Galectins (Galectin)IBA 02/2017 - 04/2012
2	Galectin 1 (LGALS1)IBA 04/2012 - 04/2009
2	Kainic Acid (Kainate)IBA 03/2006 - 11/2005
1	OligosaccharidesIBA 12/2019
1	Neuraminidase (Sialidase)IBA 01/2018
1	SynucleinsIBA 01/2018
1	LectinsIBA 01/2018
1	SphingolipidsIBA 02/2017
1	Proteins (Proteins, Gene)FDA Link 02/2017
1	GlycoconjugatesIBA 02/2017
1	G(M2) Ganglioside (Ganglioside GM2)IBA 08/2015
1	Ethanol (Ethyl Alcohol)IBA 08/2015
1	Nerve Growth Factor Receptors (Neurotrophin Receptors)IBA 07/2015
1	Glial Cell Line-Derived Neurotrophic Factor (GDNF)IBA 01/2015
1	IntegrinsIBA 04/2012
1	Glycoproteins (Glycoprotein)IBA 04/2012
1	1-nitrohydroxyphenyl-N-benzoylalanine (GAL 1)IBA 04/2009
1	aspartoacylaseIBA 01/2009
1	Sulfoglycosphingolipids (Sulfatides)IBA 01/2009
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2009
1	EnzymesIBA 01/2009
1	CerebrosidesIBA 01/2009
1	LipidsIBA 01/2009
1	gangliotetraoseIBA 11/2005
1	LigandsIBA 09/2002
1	Cholera ToxinIBA 09/2002
1	Sodium-Calcium ExchangerIBA 06/2002

Therapy/Procedure

1	Therapeutics 07/2015
1	Intraperitoneal Injections 11/2005